Author(s)

Zhengduan Lin ¹, Qiang Geng ², Xinlin Yu ², Yu Liu ²

Affiliation(s)

¹ Department of Emergency, The First People's Hospital of Neijiang, Neijiang, 641000, China
² Department of Oncology, The Second People's Hospital of Neijiang, Neijiang, 641000, China

Corresponding Author

Yu Liu

ABSTRACT

The background of this paper is Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer that is resistant to conventional treatments. High-dose-rate (HDR) combined with immune checkpoint inhibitors (ICIs) may be a promising treatment modality for advanced PSC. The main situation of the case is about a 56-year-old male with advanced poorly differentiated PSC with brain metastasis (T4N2M1b, stage IVA) received cranial radiotherapy and two cycles of platinum-based chemotherapy, followed by HDR brachytherapy (30 Gy in a single fraction) to the left lung tumor using an iridium-192 source. Partial remission was achieved after subsequent treatment with atezolizumab, an immune checkpoint inhibitor. He maintained a progression-free state for nearly 30 months until experiencing progression of intracranial lesions, while the lung lesions remained in partial remission. This case demonstrates the potential synergistic effects of combining HDR brachytherapy with immunotherapy in treating advanced PSC. The durable response observed highlights the rationale for further exploration of this innovative therapeutic strategy. Prospective studies are needed to validate these findings and optimize treatment approaches.

KEYWORDS

Pulmonary Sarcomatoid Carcinoma, Hgh-Dose-Rate Brachytherapy, Immunotherapy, Atezolizumab, Case Report

CITE THIS PAPER

Zhengduan Lin, Qiang Geng, Xinlin Yu, Yu Liu, High-Dose-Rate Brachytherapy Combined with Immunotherapy for Advanced Poorly Differentiated Pulmonary Sarcomatoid Carcinoma: A Case Report and Literature Review. MEDS Clinical Medicine (2025) Vol. 6: 20-29. DOI: http://dx.doi.org/10.23977/medsc.2025.060304.

REFERENCES

[1] Li Y, Zhang L, Jiang J, et al. [Clinical Characteristics and Prognostic Analysis of 38 Patients 
with Pulmonary Sarcomatoid Carcinoma] [J]. Zhongguo Fei Ai Za Zhi, 2015, 18(9): 537-542.
[2] Maneenil K, Xue Z, Liu M, et al. Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Pa-tients[J]. Clin Lung Cancer, 2018, 19(3): e323-e333.
[3] Li X, Wu D, Liu H, et al. Pulmonary sarcomatoid carcinoma: progress, treatment and expectations[J]. Ther Adv Med Oncol, 2020, 12: 1758835920950207.
[4] Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma [J]. J Thorac Oncol, 2013, 8(12): 1574-1577.
[5] Lee C W, Kim B H, Kim H J. Clinical outcomes of radical radiotherapy for pulmonary sarcomatoid carcinoma[J]. Radiat Oncol J, 2023, 41(3): 163-171.
[6] Hong M, Lee S W, Cho B C, et al. Multiplex analysis for the identification of plasma protein biomarkers for pre-dicting lung cancer immunotherapy response[J]. Ther Adv Med Oncol, 2024, 16: 17588359241254218.
[7] Reck M, Rodríguez-Abreu D, Robinson A G, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J]. N Engl J Med, 2016, 375(19): 1823-1833.
[8] Zhou Y, Zhang Y, Guo G, et al. Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer[J]. Clin Transl Med, 2020, 10(1): 107-115.
[9] Domblides C, Leroy K, Monnet I, et al. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcino-ma[J]. J Thorac Oncol, 2020, 15(5): 860-866.
[10] Zhang L, Lin W, Yang Z, et al. Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Cur-rent State of Art [J]. J Oncol, 2022, 2022: 8541157.
[11] Skowronek J. Brachytherapy in the treatment of lung cancer - a valuable solution[J]. J Contemp Brachytherapy, 2015, 7(4): 297-311.
[12] Xiang L, Ren P R, Li H X, et al. Effect of 3-Dimensional Interstitial High-Dose-Rate Brachytherapy With Regional Metastatic Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: 5-Year Follow-up of a Phase 2 Clinical Trial[J]. Int J Radiat Oncol Biol Phys, 2023, 115(2): 347-355.
[13] Edition S, Edge S, Byrd D. AJCC cancer staging manual. AJCC cancer staging manual, 2017.
[14] Theelen W, Peulen H M U, Lalezari F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5(9): 1276-1282.
[15] Yu S, Wang Y, He P, et al. Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment[J]. Front Oncol, 2022, 12: 809304.
[16] Zhang Z, Liu X, Chen D, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment[J]. Signal Transduct Target Ther, 2022, 7(1): 258. 
[17] Golden E B, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial[J]. Lancet Oncol, 2015, 16(7): 795-803.
[18] Jin W J, Zangl L M, Hyun M, et al. ATM inhibition augments type I interferon response and antitumor T-cell im-munity when combined with radiation therapy in murine tumor models[J]. J Immunother Cancer, 2023, 11(9).
[19] Tateishi Y, Takeda A, Horita N, et al. Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Can-cer[J]. Int J Radiat Oncol Biol Phys, 2021, 111(1): 143-151.

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine